The present invention relates to compounds of formula I wherein Y is N or C R R is hydrogen or F R is hydrogen halogen or lower alkyl substituted by halogen R is hydrogen or lower alkyl or R forms together with R a 6 membered heterocyclic ring containing CH CH O CH or CH CH NR C(O) R is hydrogen lower alkyl phenyl or benzyl R is phenyl or pyridinyl wherein the N atom in the pyridinyl group may be in different positions R is hydrogen lower alkyl or lower alkoxyalkyl R is hydrogen lower alkyl phenyl optionally substituted by halogen or lower alkoxy or is cycloalkyl or is pyridinyl optionally substituted by halogen lower alkyl lower alkoxy or =0 or is pyrimidinyl optionally substituted by lower alkyl lower alkoxy or =0 or is 1 lower alkyl pyridinyl or is pyrazinyl or is pyridazinyl optionally substituted by lower alkyl lower alkoxy or =0 or is l methylpyrrolo[2 3 b]pyridine 5 yl or is 6 imidazo[l 2 b]pyridazin 6 yl or R forms together with R a 4 5 or 6 membered heterocyclic ring containing (CH) CH CH O CH CH CH CH CH CH CH CH CH CH O CH CH or CH CH CH O CH R and R are hydrogen or lower alkyl or R4 forms together with R a saturated 5 membered ring containing CH CH CH or to a pharmaceutically acceptable salt or acid addition salt to a racemic mixture or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Parkinson s disease anxiety emesis obsessive compulsive disorder autism neuroprotection cancer depression and diabetes type 2.
